CN111920412A - 治疗脑部病症或鉴定与其相关的生物标记的方法 - Google Patents

治疗脑部病症或鉴定与其相关的生物标记的方法 Download PDF

Info

Publication number
CN111920412A
CN111920412A CN202010314939.0A CN202010314939A CN111920412A CN 111920412 A CN111920412 A CN 111920412A CN 202010314939 A CN202010314939 A CN 202010314939A CN 111920412 A CN111920412 A CN 111920412A
Authority
CN
China
Prior art keywords
patient
disorder
brain
identifying
glyx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010314939.0A
Other languages
English (en)
Chinese (zh)
Inventor
J·莫斯卡尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Publication of CN111920412A publication Critical patent/CN111920412A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
CN202010314939.0A 2013-12-13 2014-12-15 治疗脑部病症或鉴定与其相关的生物标记的方法 Pending CN111920412A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915835P 2013-12-13 2013-12-13
US61/915,835 2013-12-13
CN201480068036.1A CN106102762A (zh) 2013-12-13 2014-12-15 治疗脑部病症或鉴定与其相关的生物标记的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480068036.1A Division CN106102762A (zh) 2013-12-13 2014-12-15 治疗脑部病症或鉴定与其相关的生物标记的方法

Publications (1)

Publication Number Publication Date
CN111920412A true CN111920412A (zh) 2020-11-13

Family

ID=53371976

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010314939.0A Pending CN111920412A (zh) 2013-12-13 2014-12-15 治疗脑部病症或鉴定与其相关的生物标记的方法
CN201480068036.1A Pending CN106102762A (zh) 2013-12-13 2014-12-15 治疗脑部病症或鉴定与其相关的生物标记的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480068036.1A Pending CN106102762A (zh) 2013-12-13 2014-12-15 治疗脑部病症或鉴定与其相关的生物标记的方法

Country Status (9)

Country Link
US (1) US20160345855A1 (https=)
EP (2) EP3721799A1 (https=)
JP (2) JP2017500306A (https=)
CN (2) CN111920412A (https=)
AU (2) AU2014361822A1 (https=)
CA (1) CA2933372A1 (https=)
IL (2) IL246148A0 (https=)
MX (1) MX2016007716A (https=)
WO (1) WO2015089503A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108601814A (zh) * 2015-10-16 2018-09-28 西北大学 用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和nmda调节剂的药物组合
CN113557028A (zh) * 2019-01-11 2021-10-26 诺雷克斯股份有限公司 雷帕替奈的盐和晶型
CN110123342B (zh) * 2019-04-17 2021-06-08 西北大学 一种基于脑电波的网瘾检测方法及系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050273017A1 (en) * 2004-03-26 2005-12-08 Evian Gordon Collective brain measurement system and method
WO2007123799A2 (en) * 2006-04-03 2007-11-01 The Trustees Of The University Of Pennsylvania Assessing subject's reactivity to psychological stress using fmri
RU2496492C2 (ru) * 2006-06-15 2013-10-27 Марс, Инкорпорейтед Способы и композиции для улучшения когнитивной функции
WO2011044089A2 (en) * 2009-10-05 2011-04-14 Joseph Moskal Methods of treating depression and other related diseases
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
CA2834286A1 (en) * 2011-04-27 2012-11-01 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
WO2013106084A1 (en) * 2012-01-09 2013-07-18 Takeda Pharmaceutical Company Limited Methods and drug products for treating alzheimer's disease

Also Published As

Publication number Publication date
EP3079579A4 (en) 2017-07-19
JP2017500306A (ja) 2017-01-05
IL276431A (en) 2020-09-30
AU2014361822A1 (en) 2016-07-28
WO2015089503A2 (en) 2015-06-18
EP3079579A2 (en) 2016-10-19
CN106102762A (zh) 2016-11-09
EP3721799A1 (en) 2020-10-14
CA2933372A1 (en) 2015-06-18
US20160345855A1 (en) 2016-12-01
IL246148A0 (en) 2016-07-31
AU2019264583A1 (en) 2019-12-05
MX2016007716A (es) 2017-03-31
WO2015089503A3 (en) 2015-10-01
JP2020007333A (ja) 2020-01-16

Similar Documents

Publication Publication Date Title
US11207279B2 (en) Application of R-ketamine and salt thereof as pharmaceuticals
US20200405663A1 (en) R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder
JP7642735B2 (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
US20110034565A1 (en) Psycho-pharmaceuticals
JP2020128391A (ja) Ｎｍｄａ調節剤を使用するうつ病の治療方法
JP2019052163A (ja) 認知機能および運動機能の増強剤としてのａ２ａアンタゴニスト
JP2018065829A (ja) シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法
AU2019264583A1 (en) Treating brain disorders and biomarkers related thereto
US20120046302A1 (en) Methods of treating cns disorders
CN1395486A (zh) 用于治疗抑郁症和相关病症的包括米氮平的联合用药物
TWI831896B (zh) 用於治療多巴胺性cns病症之ly3154207劑量療法
WO2010126527A1 (en) Methods of treating cns disorders
US20240226097A1 (en) Methods of cancer treatment using a combination of btk inhibitors and pi3 kinase inhibitors
HK40040750A (en) Methods of treating brain disorders or identifying biomarkers related thereto
AU4301699A (en) Use of 4-piperidinemethanol derivatives in treatment of neurodevelopmental disorders
WO2020069008A1 (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
CN111670041A (zh) 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合
Zare et al. Wake-Promoting agents; insights into clinical use and molecular perspectives
WO2026077305A1 (zh) 一种预防或治疗神经系统变性疾病的方法和药物组合
Ojha et al. A Discursive Examination of the Neurodegenerative Alzheimer's Disease. Clin Pharmacol Biopharm, 11: 305
US20190351006A1 (en) Methods of administration of nmda receptor agonists
EP3082798B1 (en) Benzodioxol derivatives for use in the treatment of attention deficit and/or hyperactivity
JP2022510363A (ja) （ｒ）－２－（２－オキソピロリジン－１－イル）ブタンアミドと（ｓ）－２－（２－オキソピロリジン－１－イル）ブタンアミドを非ラセミ比で含む相乗的組成物
US20100227844A1 (en) Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease
HK40033382A (en) R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40040750

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201113